Seawolf Therapeutics TRIDENT DNA delivery platform

Seawolf Therapeutics Surfaces With $100M and a $1.2B Sanofi Deal to Rewrite DNA Medicine

November 18, 2026

A San Diego Biotech Steps Out of the Shadows With a Platform That Could Change How We Treat Disease

On November 16, 2026, Seawolf Therapeutics announced its emergence from stealth — along with $100 million in Series A financing and a multi-target research collaboration and exclusive licensing agreement with Sanofi worth up to $1.2 billion in milestone payments, plus tiered royalties. It is a debut that the life sciences world has taken notice of.

The Series A was led by Versant Ventures and MPM BioImpact, with participation from Novartis Venture Fund, Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, and the National Bleeding Disorders Foundation's philanthropic venture arm, Pathway to Cures, among others. That is a who's who of serious life sciences capital at the table from day one.

Related

What Seawolf Is Building

Seawolf's core technology is called TRIDENT — Targeted RNA-Induced DNA Expression via Nuclear Translocation. It is a redosable lipid nanoparticle (LNP)-based DNA delivery system designed to solve a problem that has limited gene medicine for decades: how to get DNA payloads reliably into the nucleus of cells, durably, safely, and in a way that can be dosed more than once.

Conventional LNP technologies were developed for RNA delivery. Delivering DNA is harder. The nucleus is a different destination. Seawolf says TRIDENT does it by pairing a proprietary LNP with an immune-quiet DNA payload and an auxiliary factor that opens nuclear access. The result, according to the company, matches the potency and scalability of RNA-based LNP therapies while delivering the durability that RNA cannot — because DNA, once expressed, keeps working far longer than RNA does.

Seawolf has demonstrated proof-of-concept in both primate and murine models of metabolic and rare diseases, with sustained protein expression above therapeutic levels at doses described as safe and well-tolerated in primates. Those are meaningful milestones for a company announcing its Series A. Many biotechs raise capital without non-human primate data in hand.

The Sanofi Deal

The collaboration with Sanofi covers undisclosed DNA-based therapies for bleeding disorders and additional indications. Sanofi will get exclusive licensing rights; Seawolf will receive milestone payments totalling up to $1.2 billion if programmes advance, along with tiered royalties on any products that reach the market. For a Series A company to announce a deal of this scale on launch day signals that Sanofi saw something scientifically compelling, not just a promising concept.

Seawolf's lead proprietary programme targets metabolic diseases, with potential applications in areas including obesity, muscle loss, and osteoporosis. CEO Elizabeth Alcamo, Ph.D., has stated the company aims to select a development candidate by late 2027 and file to begin human trials by the end of 2028.

Why This Matters

Gene medicine has been a field of enormous promise and genuine complexity. Viral vectors — adenoviruses and adeno-associated viruses — have been the workhorse for DNA delivery for many years, but they come with real limitations: immune responses that can prevent repeat dosing, manufacturing challenges at scale, and safety signals that have occasionally halted programmes. LNP-based approaches solved many of those problems for RNA, as the mRNA vaccine era demonstrated at scale. The unsolved question was whether LNPs could do the same for DNA.

Seawolf is placing a focused, well-funded bet that the answer is yes — and that a company built from scratch around that specific problem can solve it better than those who adapted RNA tools retrospectively.

What This Means for Startups in Singapore, China, and Asia

Asia's biotech ecosystem has grown significantly over the past decade. Singapore, in particular, has built a robust base of research institutions, clinical trial infrastructure, and regulatory sophistication that positions it as a regional hub. China has produced a generation of biopharmaceutical companies with deep capital and global ambitions. South Korea and Australia are producing serious science in cell and gene therapy.

Seawolf's story holds lessons for all of them. First, the power of a narrow, defensible platform bet: rather than building a broad pipeline early, Seawolf went deep on one delivery problem and demonstrated results in primates before going public. Second, the importance of pharma partnership as validation rather than exit: the Sanofi deal signals scientific credibility at a stage when most companies are still building towards an IND. Third, the value of syndicate construction — the breadth of Seawolf's investor group, from large venture funds to pharma corporate venturing arms to disease-focused philanthropic vehicles, is itself a form of de-risked social proof.

For Asian startups building in gene therapy or precision medicine, Seawolf's debut is a data point about what a credible Series A narrative looks like in the current market.

how can ASIA startups compete globally

Building world-class science is necessary but not sufficient. How founders and their teams communicate that science — to investors, to partners, to regulators, to the talent they want to attract — determines whether a great platform becomes a great company. According to the Sjodin Communications State of Sales Presentations (Phase Three, 2025), 55% of study participants reported receiving little or no presentation skills training. That gap exists in biotech boardrooms and investor meetings just as it does in enterprise sales. Seawolf's ability to close a $1.2B Sanofi deal and attract a blue-chip syndicate on debut day reflects not just the quality of its science but the quality of its communication at every level. For Asia's founders building deep-tech or biotech, closing that presentation skills gap can be the difference between a deal that happens and one that is passed on. The science earns the seat at the table. The speaking gets the signature.

Work With Jason

DreaMaker Ventures founder Jason Lim works with startup founders and sales teams on the presentation skills and speaking skills that move deals forward — before Series A and beyond. Learn more at start.dreamaker.club/jason.

Related

Jason Lim

Jason Lim

I wanted more than just survival—I wanted control, options, and a life on my terms. The obsession with this goal led me to several places and acquired unique skillsets, in order to accomplish my goals. I found the secrets in my rock bottom, now I want to share them with you

Instagram logo icon
Youtube logo icon
Back to Blog